Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07

Submission of Matters to a Vote of Security Holders

Our annual meeting of stockholders was held on April 26, 2018 to consider and vote on the following proposals. The voting results with respect to each matter are set forth below:

(1)

Election of Class III Directors:

Name of Director

For

Withheld

Broker

Non-Votes

Philippe J. Amouyal

88,445,363

3,760,056

8,190,338

Lonnel Coats

89,600,508

2,604,911

8,190,338

Frank P. Palantoni

91,164,315

1,041,104

8,190,338

For

Against

Abstain

BrokerNon-Votes

(2)

Advisory vote to approve the compensation paid to our named executive officers

90,919,786

969,663

315,970

8,190,338

For

Against

Abstain

BrokerNon-Votes

(3)

Ratification and approval of the appointment of Ernst& Young LLP as our independent auditors for the fiscal year ending December31, 2018

99,651,301

481,407

263,049


About Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company’s other programs include LX1033, LX2931 and LX7101.